Tiny Ignyta ' s Lung Cancer Drug Bested Pfizer ' s. Probably. Will We Ever Know For Sure?
Results of a 32-patient study of a drug made by Ignyta Pharmaceuticals, a San Diego-based drugmaker, are a best case scenario for the company. The drug shrank tumors in 79% of patients and kept workingabout 10 months longer than the current drug, Pfizer ’s Xalkori, did in earlier clinical trials.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:RXDX NYSE:PFE Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Pfizer | Pharmaceuticals | Study